List Bio

List Biotherapeutics, Inc. is dedicated to meeting the needs of companies seeking to rapidly and cost-effectively advance Live Biotherapeutic Products (LBP) through Phase 3 clinical development and commercial manufacturing. List Bio was established in October 2021 under its parent company, South Korea's Genome & Company (KOSDAQ: 314130), complementing the Phase 1 and Phase 2 clinical production capabilities of its sister company, List Labs. Together, the two companies offer end-to-end manufacturing solutions for LBP.